Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

PRIME Time: Smaller Companies In Focus As EMA Launches Priority Medicines Scheme

This article was originally published in The Pink Sheet Daily

Executive Summary

In exceptional cases, smaller and medium-sized companies might obtain PRIME designation in proof of principle stage, underscoring the expectation that they will particularly benefit from the program.

You may also be interested in...



First EU PRIME Designations Go To Biogen, ChemoCentryx, Kite, NovImmune

The first four drugs European Medicines Agency selects for its new priority review program include Biogen's Alzheimer's disease treatment aducanumab. Fourteen applicants did not garner PRIME status.

Many PRIME Applicants Are Missing Pediatric Investigation Plans

Aside from pediatrics research issue, most of the first batch of applications for the new priority review scheme were "in scope," with numerous therapeutic areas targeted.

EMA's PRIME: Helpful But Not A Panacea

European Medicines Agency will try "just as hard" to aid companies who tap into other EU regulatory tools aimed at fostering quicker reviews, official says at BIA/MHRA conference.

Related Content

Topics

UsernamePublicRestriction

Register

LL1135495

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel